This page shows the latest Breyanzi news and features for those working in and with pharma, biotech and healthcare.
T-cell malignancies have been seen in patients treated with several approved products in the class, including Bristol Myers Squibb’s (BMS) Abecma (idecabtagene vicleucel) and Breyanzi (lisocabtagene maraleucel), Johnson &Johnson
up from $24m in Q2, while Breyanzi (lisocabtagene maraleucel), launched this year in lymphoma, had $30m in sales, up from $17m earlier in the year.
New results follow success of BMS’ Breyanzi in the same patient population and setting. ... The ongoing TRANSFORM study is evaluating Breyanzi (lisocabtagene maraleucel) compared to current standard of care regimens for LBCL, including high-dose
Breyanzi demonstrated a statistically significant improvement in event-free survival compared to standard of care. ... The ongoing TRANSFORM study is evaluating Breyanzi (lisocabtagene maraleucel) compared to current standard of care regimens for LBCL,
Also approved for the treatment of large B-cell lymphoma is Novartis’ rival CAR-T therapy Kymriah (tisagenlecleucel) and Bristol Myers Squibb’s (BMS) Breyanzi (lisocabtagene maraleucel), which are both approved
The FDA's approval of Breyanzi came a year after the start of the review. ... Breyanzi joins other approved CAR T therapies on the market from Gilead/Kite and Novartis.
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
No results were found
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...